Bradford Whitmore Biography and Net Worth

Major Shareholder of Clearside Biomedical


Bradford T. Whitmore serves as Independent Chairman of the Board of the Company. Mr. Whitmore has been a director of the Company since June 2007 and Chair of our Board of Directors since March 2010. Since 1985, he has been the Managing Partner of Grace Brothers LP, an investment firm that holds approximately 3% of the outstanding shares of our common stock. Mr. Whitmore and Grace Brothers LP collectively hold or claim beneficial ownership of 34.9% of the outstanding shares of our common stock. Mr. Whitmore has a BS in Mechanical Engineering from Purdue University and an MBA from Northwestern University’s J.L. Kellogg Graduate School of Management. Over the past five years, Mr. Whitmore has served as a director of several privately held companies in which Grace Brothers LP and its affiliates held investments as well as not-for-profit organizations. Mr. Whitmore has been nominated for re-election to our Board of Directors because of his corporate development expertise and significant expertise in corporate financial matters.

What is Bradford T. Whitmore's net worth?

The estimated net worth of Bradford T. Whitmore is at least $7.06 million as of February 7th, 2024. Mr. Whitmore owns 4,495,034 shares of Clearside Biomedical stock worth more than $7,057,203 as of March 28th. This net worth evaluation does not reflect any other assets that Mr. Whitmore may own. Learn More about Bradford T. Whitmore's net worth.

How do I contact Bradford T. Whitmore?

The corporate mailing address for Mr. Whitmore and other Clearside Biomedical executives is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. Clearside Biomedical can also be reached via phone at (678) 270-3631 and via email at [email protected]. Learn More on Bradford T. Whitmore's contact information.

Has Bradford T. Whitmore been buying or selling shares of Clearside Biomedical?

During the last ninety days, Bradford T. Whitmore has bought $599,999.40 in Clearside Biomedical stock. Most recently, on Wednesday, February 7th, Bradford T. Whitmore bought 444,444 shares of Clearside Biomedical stock. The stock was acquired at an average cost of $1.35 per share, with a total value of $599,999.40. Following the completion of the transaction, the insider now directly owns 4,495,034 shares of the company's stock, valued at $6,068,295.90. Learn More on Bradford T. Whitmore's trading history.

Who are Clearside Biomedical's active insiders?

Clearside Biomedical's insider roster includes Richard Burke (Director), Thomas Ciulla (Insider), Charles Deignan (CFO), George Lasezkay (CEO), and Bradford Whitmore (Major Shareholder). Learn More on Clearside Biomedical's active insiders.

Are insiders buying or selling shares of Clearside Biomedical?

In the last year, Clearside Biomedical insiders bought shares 6 times. They purchased a total of 559,410 shares worth more than $713,244.24. In the last year, insiders at the sold shares 2 times. They sold a total of 30,900 shares worth more than $39,372.00. The most recent insider tranaction occured on March, 20th when insider Ngai Hang Victor Chong bought 30,000 shares worth more than $48,000.00. Insiders at Clearside Biomedical own 9.8% of the company. Learn More about insider trades at Clearside Biomedical.

Information on this page was last updated on 3/20/2024.

Bradford T. Whitmore Insider Trading History at Clearside Biomedical

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/7/2024Buy444,444$1.35$599,999.404,495,034View SEC Filing Icon  
11/1/2023Buy64,366$0.74$47,630.844,050,590View SEC Filing Icon  
10/30/2023Buy600$0.69$414.003,915,412View SEC Filing Icon  
9/1/2021Sell213,203$6.89$1,468,968.673,529,845View SEC Filing Icon  
8/30/2021Sell99,400$7.06$701,764.003,529,845View SEC Filing Icon  
1/6/2021Buy350,750$2.85$999,637.503,529,845View SEC Filing Icon  
12/24/2020Buy51,195$1.95$99,830.253,179,095View SEC Filing Icon  
12/2/2020Buy53,900$1.95$105,105.003,127,900View SEC Filing Icon  
11/24/2020Buy62,000$1.65$102,300.003,074,000View SEC Filing Icon  
11/16/2020Buy62,000$1.69$104,780.00
8/12/2020Buy300,000$1.63$489,000.002,900,000View SEC Filing Icon  
See Full Table

Bradford T. Whitmore Buying and Selling Activity at Clearside Biomedical

This chart shows Bradford T Whitmore's buying and selling at Clearside Biomedical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Clearside Biomedical Company Overview

Clearside Biomedical logo
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Read More

Today's Range

Now: $1.57
Low: $1.50
High: $1.73

50 Day Range

MA: $1.44
Low: $1.20
High: $2.02

2 Week Range

Now: $1.57
Low: $0.65
High: $2.12

Volume

403,737 shs

Average Volume

351,720 shs

Market Capitalization

$117.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.28